<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ovarian hyperthecosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ovarian hyperthecosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Ovarian hyperthecosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">André P van Beek, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Astrid EP Cantineau, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William F Crowley, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Ovarian hyperthecosis (OHT), a disorder characterized by severe hyperandrogenism and insulin resistance, is seen primarily in postmenopausal females. The term hyperthecosis refers to the presence of nests of luteinized theca cells in the ovarian stroma due to differentiation of the ovarian interstitial cells into steroidogenically active luteinized stromal cells  (<a class="graphic graphic_picture graphicRef75548" href="/z/d/graphic/75548.html" rel="external">picture 1</a>).The result is greater production of androgens.</p><p>Females with OHT typically present during their postmenopausal years, and occasionally premenopausal years, with worsening hirsutism, virilization, obesity, and insulin resistance. The clinical presentation, diagnosis, and treatment of OHT are discussed here. A more comprehensive review of the approach to severe hyperandrogenism in postmenopausal females, including a discussion of androgen-secreting ovarian and adrenal tumors is found separately. Severe hyperandrogenism associated with hypercortisolism and premenopausal hyperandrogenism are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13917.html" rel="external">"Evaluation and management of postmenopausal hyperandrogenism", section on 'Women with virilization or severe hyperandrogenemia'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7441.html" rel="external">"Evaluation of premenopausal women with hirsutism"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">"Management of hirsutism in premenopausal women"</a>.)</p><p></p><p class="headingAnchor" id="H14632347"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H1333873718"><span class="h2">Severe hyperandrogenism</span><span class="headingEndMark"> — </span>The majority of patients with ovarian hyperthecosis (OHT) are postmenopausal females who present with severe hyperandrogenism, characterized by gradual onset, followed by slowly progressive acne and hirsutism, and, later, virilization [<a href="#rid1">1-4</a>]. While hirsutism and female-pattern hair loss are the most common symptoms of hyperandrogenism in postmenopausal females, virilizing signs (male-pattern hair loss, clitoromegaly, lowering of the voice, increased muscle strength, and an anabolic appearance) are seen only with disorders of severe androgen excess, including OHT. (See  <a class="medical medical_review" href="/z/d/html/7441.html" rel="external">"Evaluation of premenopausal women with hirsutism"</a> and  <a class="medical medical_review" href="/z/d/html/13917.html" rel="external">"Evaluation and management of postmenopausal hyperandrogenism"</a>.)</p><p>The slow onset and progression helps distinguish OHT from other causes of severe hyperandrogenism (androgen-secreting ovarian or adrenal tumors), which present with a more rapid onset and faster progression of hyperandrogenic symptoms. (See  <a class="medical medical_review" href="/z/d/html/13917.html" rel="external">"Evaluation and management of postmenopausal hyperandrogenism", section on 'Approach to the patient'</a>.)</p><p>Some females who develop OHT after menopause report a history of polycystic ovary syndrome (PCOS) in their premenopausal years. OHT has sometimes been referred to as an extreme form of PCOS, but the vast majority of females with PCOS do not develop OHT.</p><p class="headingAnchor" id="H2249147117"><span class="h2">Obesity and insulin resistance</span><span class="headingEndMark"> — </span>Almost all females with OHT have obesity, insulin resistance, and hyperinsulinemia [<a href="#rid5">5,6</a>]. These individuals are also at increased risk for type 2 diabetes and, possibly, cardiovascular disease [<a href="#rid1">1</a>]. Additional physical findings include skin tags and acanthosis nigricans. (See  <a class="medical medical_review" href="/z/d/html/1762.html" rel="external">"Insulin resistance: Definition and clinical spectrum"</a> and  <a class="medical medical_review" href="/z/d/html/1784.html" rel="external">"Metabolic syndrome (insulin resistance syndrome or syndrome X)"</a>.)</p><p class="headingAnchor" id="H2194569025"><span class="h2">Endometrial hyperplasia and cancer</span><span class="headingEndMark"> — </span>The risk of uterine bleeding, endometrial hyperplasia, and endometrial carcinoma appears to be increased in postmenopausal females with OHT, due to aromatization of large amounts of testosterone to estrogen [<a href="#rid1">1,7</a>]. An increased risk of endometrial hyperplasia is seen in any setting of excess unopposed estrogen, either endogenous or exogenous. (See  <a class="medical medical_review" href="/z/d/html/3249.html" rel="external">"Endometrial carcinoma: Epidemiology, risk factors, and prevention", section on 'Chronically increased estrogen levels or estrogenic activity'</a>.)</p><p class="headingAnchor" id="H952680715"><span class="h2">Biochemical findings</span><span class="headingEndMark"> — </span>Patients with hyperthecosis have the following biochemical findings (see <a class="local">'Initial laboratory testing'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>Serum total testosterone (T) concentrations &gt;150 ng/dL (&gt;5.2 nmol/L) [<a href="#rid8">8-11</a>]. It is the single most important biochemical finding, and one that triggers further evaluation for causes of severe hyperandrogenism. Serum T concentrations tend to be higher in patients with androgen-secreting tumors than OHT, but hyperthecosis is unlikely if serum total testosterone is below 150 ng/dL (&gt;5.2 nmol/L). (See  <a class="medical medical_review" href="/z/d/html/13917.html" rel="external">"Evaluation and management of postmenopausal hyperandrogenism", section on 'Women with virilization or severe hyperandrogenemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Normal or suppressed luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [<a href="#rid12">12</a>]. However, given the postmenopausal status of most of these patients, their endogenous LH secretion covers a wide range of serum levels, and multiple determinations of T and LH may be needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Normal serum androstenedione or dehydroepiandrosterone sulfate (DHEAS) concentrations [<a href="#rid13">13</a>]. Both may be high in adrenocortical carcinoma [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unfavorable lipid profiles (increase in low-density lipoprotein [LDL] and triglycerides, decrease in high-density lipoprotein [HDL]) related to the hyperandrogenemia [<a href="#rid14">14</a>].</p><p></p><p class="headingAnchor" id="H1859157243"><span class="h2">Histology</span><span class="headingEndMark"> — </span>The term hyperthecosis refers to the presence of nests of luteinized theca cells in the ovarian stroma due to differentiation of the ovarian interstitial cells into steroidogenically active luteinized stromal cells  (<a class="graphic graphic_picture graphicRef75548" href="/z/d/graphic/75548.html" rel="external">picture 1</a>). These nests or islands of luteinized theca cells are scattered throughout the stroma of the ovary, rather than being confined to areas around cystic follicles as in the polycystic ovary syndrome (PCOS). The result is greater production of androgens. The precise etiology of OHT is still unclear.</p><p class="headingAnchor" id="H40953583"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H3826070240"><span class="h2">Initial laboratory testing</span><span class="headingEndMark"> — </span>While ovarian hyperthecosis (OHT) is one cause of severe hyperandrogenism, other causes include androgen-secreting ovarian and adrenal tumors (see <a class="local">'Differential diagnosis'</a> below). The initial laboratory testing in any female who presents with severe hyperandrogenism (virilization) and no prior biochemical testing includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum total testosterone (T).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum luteinizing hormone (LH) and follicle-stimulating hormone (FSH).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most experts also measure other androgens (dehydroepiandrosterone sulfate [DHEAS] and androstenedione) in a female who presents with severe hyperandrogenism, primarily to identify adrenocortical carcinomas [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We do not test for insulin resistance, as there is no agreement on how to best assess insulin resistance, and its presence does not change management. However, we do suggest evaluating for type 2 diabetes as described below. (See <a class="local">'Ovarian hyperthecosis'</a> below.)</p><p></p><p class="headingAnchor" id="H952680501"><span class="h2">Imaging studies</span><span class="headingEndMark"> — </span>In females who present with severe hyperandrogenism (eg, virilization) and an increased testosterone concentration &gt;150 ng/dL (&gt;5.2 nmol/L), the next step of the evaluation is to perform additional imaging to find the source of androgen production. Imaging of the ovaries (ultrasound and magnetic resonance imaging [MRI] if needed) and adrenals (by computed tomography [CT] scan and/or MRI) are performed to rule out testosterone-producing tumors. (See  <a class="medical medical_review" href="/z/d/html/13917.html" rel="external">"Evaluation and management of postmenopausal hyperandrogenism", section on 'Women with virilization or severe hyperandrogenemia'</a> and <a class="local">'Diagnosis'</a> below.)</p><p class="headingAnchor" id="H952680508"><span class="h3">Ultrasonography</span><span class="headingEndMark"> — </span>In postmenopausal females with hyperthecosis, ovarian size is usually increased compared with normal females [<a href="#rid15">15</a>]. In addition, transvaginal ultrasound in females with hyperthecosis usually shows a bilateral increase in ovarian stroma [<a href="#rid16">16-18</a>]. Unlike polycystic ovary syndrome (PCOS), where the ovaries characteristically have a polycystic/multifollicular appearance with 20 or more antral follicles of 2 to 9 mm per ovary and/or ovarian volume &gt;10 cm<sup>3</sup> [<a href="#rid19">19</a>], few cysts are seen in severe hyperthecosis and the ovaries appear more solid  (<a class="graphic graphic_diagnosticimage graphicRef68176" href="/z/d/graphic/68176.html" rel="external">image 1</a>) [<a href="#rid16">16</a>]. Some types of androgen-secreting ovarian tumors are too small to be visualized.</p><p>The ovaries are enlarged in females with OHT, although normal ovaries have been reported occasionally. A normal, postmenopausal ovary has a mean volume between 1.25 to 3.7 cm<sup>3</sup> [<a href="#rid20">20,21</a>], but in OHT, the average volume may be up to 10 cm<sup>3</sup> [<a href="#rid6">6,15</a>].</p><p class="headingAnchor" id="H952680515"><span class="h3">MRI</span><span class="headingEndMark"> — </span>Magnetic resonance imaging (MRI) findings in OHT include symmetric bilateral ovarian enlargement, with homogeneous T2-hypointensity and mild enhancement of the ovaries [<a href="#rid22">22,23</a>].</p><p class="headingAnchor" id="H2723858355"><span class="h3">Ovarian and adrenal venous sampling</span><span class="headingEndMark"> — </span>Combined ovarian and adrenal vein sampling (selective venous sampling) is a procedure performed on occasion for further evaluation in females with high serum T concentrations (T &gt;150 ng/dL [5.2 nmol/L]), and normal ovarian and adrenal imaging [<a href="#rid24">24,25</a>]. We do not perform this procedure in postmenopausal females with negative ovarian and adrenal imaging, because it does not change management (bilateral oophorectomy). The ovary is likely to be the source of androgen hypersecretion because adrenal tumors are almost always visualized on adrenal CT [<a href="#rid26">26,27</a>], while ovarian tumors are often too small to be seen on imaging studies [<a href="#rid28">28</a>]. This procedure is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/13917.html" rel="external">"Evaluation and management of postmenopausal hyperandrogenism", section on 'Ovarian and adrenal vein sampling'</a>.)</p><p class="headingAnchor" id="H4202719785"><span class="h2">Role of gonadotropin-releasing hormone (GnRH) agonist testing</span><span class="headingEndMark"> — </span>Some experts perform GnRH agonist testing for diagnostic purposes in patients with testosterone concentrations &gt;150 ng/dL (&gt;5.2 nmol/L) in whom the diagnosis of hyperthecosis is considered based on biochemical findings and imaging.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>OHT versus androgen-secreting tumors</strong> – This test cannot reliably distinguish between hyperthecosis and androgen-secreting ovarian tumors as some of these are gonadotropin dependent [<a href="#rid29">29-31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>OHT with a coexisting adrenal incidentaloma</strong> – The test may be useful in patients with apparent OHT with a coexisting adrenal incidentaloma on imaging, which may occur in 4 to 10 percent of patients. Suppression of serum testosterone after the dose of GnRH agonist confirms that the source of androgen excess is the ovary and not the adrenal incidentaloma. (See  <a class="medical medical_review" href="/z/d/html/137.html" rel="external">"Clinical presentation and evaluation of adrenocortical tumors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protocol</strong> – Immediately before and four weeks after intramuscular injection of a GnRH agonist, T, LH, and FSH should be determined. Suppression of T confirms the presence of LH-dependent ovarian T production and may provide evidence for successful long-term treatment with GnRH agonists [<a href="#rid29">29-32</a>].</p><p></p><p class="bulletIndent1">Acute administration of a GnRH antagonist would be a more rapid way to determine the presence of LH-dependent ovarian T production. However, antagonists have not yet been studied in this setting. </p><p></p><p class="headingAnchor" id="H14632553"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H1667429552"><span class="h2">Ovarian hyperthecosis</span><span class="headingEndMark"> — </span>The gold standard for confirming the diagnosis of ovarian hyperthecosis (OHT) is histopathologic examination of the ovaries and demonstration of the presence of nests of luteinized cells in the ovarian stroma  (<a class="graphic graphic_picture graphicRef75548" href="/z/d/graphic/75548.html" rel="external">picture 1</a>) [<a href="#rid33">33-35</a>]. Occasionally, nodules are scattered throughout the stroma. In practice, the definitive diagnosis is typically made by the pathologist after surgical removal of the ovary. (See <a class="local">'Management'</a> below.)</p><p>OHT should be suspected in females with a longstanding history of hirsutism that progressively worsens in the postmenopausal years. As described above, females become virilized and have obesity, insulin resistance, and a serum total testosterone (T) concentration &gt;150 ng/dL (&gt;5.2 nmol/L). A serum total T lower than this effectively rules out the diagnosis. Unfortunately, virilization, which is not reversible, has already occurred by the time many patients first present.</p><p>These females typically exhibit features of the metabolic syndrome and are thus potentially at increased risk of cardiometabolic sequelae. Evaluation for type 2 diabetes should be performed with a fasting blood glucose or glycated hemoglobin (A1C). It is possible that a two-hour oral glucose tolerance test is more sensitive in this population (as it is in females with polycystic ovary syndrome [PCOS]), but this has not yet been established. (See <a class="local">'Obesity and insulin resistance'</a> above and  <a class="medical medical_review" href="/z/d/html/7385.html" rel="external">"Diagnosis of polycystic ovary syndrome in adults", section on 'Cardiometabolic risk assessment'</a>.)</p><p class="headingAnchor" id="H14587957"><span class="h2">Differential diagnosis</span></p><p class="headingAnchor" id="H26069224"><span class="h3">Androgen-secreting ovarian and adrenal tumors</span><span class="headingEndMark"> — </span>In postmenopausal females with severe hyperandrogenism, androgen-secreting ovarian and adrenal tumors, although rare, are the most important disorders to address in the differential diagnosis. Serum T concentrations tend to be considerably higher than those seen with OHT but an important overlap may be found [<a href="#rid18">18</a>]  (<a class="graphic graphic_table graphicRef83495" href="/z/d/graphic/83495.html" rel="external">table 1</a>). While OHT has features that are similar to androgen-secreting tumors, differences include an increase in ovarian volume (usually), obesity and insulin resistance, and a slower progression of symptoms.</p><p>Females with androgen-secreting tumors typically present with rapid onset and progression of hirsutism and virilization. Pelvic magnetic resonance imaging (MRI) can be useful for differentiating between androgen-secreting ovarian tumors and OHT [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/13917.html" rel="external">"Evaluation and management of postmenopausal hyperandrogenism", section on 'Ovarian and adrenal neoplasms'</a> and  <a class="medical medical_review" href="/z/d/html/16833.html" rel="external">"Sex cord-stromal tumors of the ovary: Epidemiology, clinical features, and diagnosis in adults"</a>.)</p><p class="headingAnchor" id="H2209056453"><span class="h3">Disorders in premenopausal females</span><span class="headingEndMark"> — </span>OHT is only occasionally diagnosed in premenopausal females [<a href="#rid2">2</a>]. In premenopausal females who do have severe hyperandrogenism, androgen-secreting ovarian and adrenal tumors must be considered, but they are very rare. The approach to evaluating females with severe hyperandrogenism, including testing for possible androgen-secreting tumors, is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7441.html" rel="external">"Evaluation of premenopausal women with hirsutism", section on 'Additional evaluation for severe hyperandrogenemia'</a>.)</p><p>The vast majority of hyperandrogenic premenopausal females have PCOS, which is not associated with severe hyperandrogenism. These females do not become virilized, and they have lower serum T concentrations and milder insulin resistance when compared with females with hyperthecosis. In addition, the ultrasound appearance of the ovaries is different as described above. (See <a class="local">'Ultrasonography'</a> above and  <a class="medical medical_review" href="/z/d/html/7436.html" rel="external">"Clinical manifestations of polycystic ovary syndrome in adults"</a>.)</p><p>Premenopausal females with nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency have a similar clinical presentation as those with PCOS, ie, hyperandrogenism (hirsutism), but <strong>not</strong> severe hyperandrogenism, so they do not become virilized.</p><p>PCOS and nonclassic 21-hydroxylase deficiency are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7436.html" rel="external">"Clinical manifestations of polycystic ovary syndrome in adults"</a> and  <a class="medical medical_review" href="/z/d/html/147.html" rel="external">"Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a>.)</p><p class="headingAnchor" id="H14632546"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H1231507202"><span class="h2">Goals</span><span class="headingEndMark"> — </span>Treatment of ovarian hyperthecosis (OHT) should include therapy for hyperandrogenism (hirsutism and virilization), anovulation, obesity, and insulin resistance. The primary goal of treatment is to eliminate the excessive testosterone (T) production. However, normalization of hyperandrogenism after surgery for androgen-secreting ovarian tumors is not always followed by an improvement in body weight or insulin sensitivity [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H3558180812"><span class="h2">Strategies to eliminate/reduce testosterone production</span><span class="headingEndMark"> — </span>In postmenopausal females and the rare premenopausal patient with OHT who does not plan to pursue future fertility, the treatment options to eliminate ovarian T production are surgery (bilateral oophorectomy) and gonadotropin-releasing hormone (GnRH) agonist therapy. We suggest surgery for most females.</p><p class="headingAnchor" id="H2858065279"><span class="h3">Bilateral oophorectomy</span><span class="headingEndMark"> — </span>The treatment of choice for most postmenopausal females with likely OHT is laparoscopic bilateral salpingo-oophorectomy, which provides a definitive solution for the hyperandrogenism, as well as a surgical sample to confirm the diagnosis by histology [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H262498738"><span class="h3">GnRH agonist therapy</span><span class="headingEndMark"> — </span>Long-term gonadotropin-releasing hormone (GnRH) agonist treatment (with estrogen-progestin add-back in premenopausal females) is an alternative, particularly in females who have an increased risk for surgery due to comorbidities or who are unwilling to undergo bilateral oophorectomy [<a href="#rid5">5,29,37,38</a>]. Descriptions for GnRH agonist with estrogen-progestin add-back regimens are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7416.html" rel="external">"Endometriosis: Long-term treatment with gonadotropin-releasing hormone agonists", section on 'Estrogen plus progestin add-back'</a>.)</p><p>In a report of three postmenopausal females with virilization, ovarian hyperandrogenism, and negative imaging, GnRH agonist treatment resulted in androgen suppression within the first one to three months [<a href="#rid32">32</a>]. Total treatment duration was between 8 and 13 months; after stopping therapy, T concentrations remained low in two but increased again in the third. Since no histologic diagnosis is available as final confirmation in females treated medically rather than surgically, it is recommended that all patients treated with GnRH agonists receive careful follow-up, including periodic testing of androgen levels and ovarian imaging. Another strategy would be use of a GnRH antagonist, but studies are not yet available.</p><p>If serum T concentrations do not decrease after several months of GnRH agonist therapy, we suggest surgery (bilateral oophorectomy) for histologic diagnosis.</p><p class="headingAnchor" id="H1627659367"><span class="h3">Outcomes</span></p><p class="bulletIndent1"><span class="glyph">●</span>Virilizing signs and symptoms are not reversible. However, the less severe signs of hyperandrogenism, such as hirsutism and acne should begin to improve over time. Anti-androgen therapy may be helpful in some females. (See <a class="local">'Additional therapies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic profiles may not improve in spite of the dramatic reduction in serum androgens. The reasons for this are unclear. The impact of androgen suppression on insulin sensitivity was addressed in a trial of 35 postmenopausal females without diabetes assigned to receive <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> or <a class="drug drug_general" data-topicid="9549" href="/z/d/drug information/9549.html" rel="external">leuprolide</a> acetate [<a href="#rid39">39</a>]. Metformin therapy reduced serum T and improved insulin resistance and insulin sensitivity. Leuprolide acetate reduced serum T to a greater degree than metformin, but no improvement in insulin parameters was seen.</p><p></p><p class="headingAnchor" id="H214637548"><span class="h3">Additional therapies</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hirsutism: Anti-androgen therapy</strong> – Anti-androgen therapy, such as <a class="drug drug_general" data-topicid="9943" href="/z/d/drug information/9943.html" rel="external">spironolactone</a>, can be used to suppress the actions of testosterone and mitigate the common clinical manifestations of hyperandrogenism, such as hirsutism, acne, and hair loss in females with OHT. (See  <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">"Management of hirsutism in premenopausal women", section on 'Antiandrogens'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolic issues: Obesity and type 2 diabetes</strong> – Weight reduction in females with OHT and obesity results in an increase in insulin sensitivity [<a href="#rid40">40</a>]. In patients with OHT and established type 2 diabetes mellitus, <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> is first-line therapy for glycemic management [<a href="#rid39">39</a>]. Other effects include potential weight loss and a modest decrease in serum triglycerides and low-density lipoprotein (LDL). Metformin is not effective for hirsutism. (See  <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">"Management of hirsutism in premenopausal women", section on 'Metformin'</a> and  <a class="medical medical_review" href="/z/d/html/1809.html" rel="external">"Metformin in the treatment of adults with type 2 diabetes mellitus", section on 'Clinical outcomes'</a>.)</p><p></p><p class="headingAnchor" id="H1484280480"><span class="h2">Premenopausal females pursuing fertility</span><span class="headingEndMark"> — </span>As noted, OHT is rare in premenopausal females, and the management of patients who have not completed childbearing is challenging. Ovulation induction is sometimes attempted, but success rates are likely low.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Virilization</strong> – While awaiting possible ovulation induction, we suggest starting gonadotropin-releasing hormone (GnRH) agonist therapy to prevent worsening of the patient's virilization.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anovulatory infertility</strong> – There is little information on success rates with ovulation induction in the rare premenopausal females with OHT who desires fertility. However, pregnancy rates are likely to be very low due to factors such as obesity, abnormal ovarian architecture, and extremely high serum and intraovarian androgens. If ovulation induction is attempted, we suggest <a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">letrozole</a>, the drug of choice for females with polycystic ovary syndrome (PCOS). If unsuccessful, <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">clomiphene</a> can be tried. However, in a study of five females with OHT, none ovulated in response to clomiphene [<a href="#rid12">12</a>]. Gonadotropin therapy has not been studied. (See  <a class="medical medical_review" href="/z/d/html/7407.html" rel="external">"Overview of ovulation induction"</a>.)</p><p></p><p class="bulletIndent1">There are no published reports on the success of ovarian drilling in restoring ovulation, and procedures aiming at reducing ovarian stromal volume should be discouraged and considered as a last resort only. (See  <a class="medical medical_review" href="/z/d/html/3279.html" rel="external">"Female infertility: Reproductive surgery", section on 'Ovarian wedge resection and drilling'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hirsutism</strong> – Other options include treatment of hirsutism by local therapy, oral contraceptives, and anti-androgens. (See <a class="local">'Additional therapies'</a> above and  <a class="medical medical_review" href="/z/d/html/7444.html" rel="external">"Management of hirsutism in premenopausal women"</a>.)</p><p></p><p class="headingAnchor" id="H8648909"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110632.html" rel="external">"Society guideline links: Hirsutism"</a>.)</p><p class="headingAnchor" id="H14632538"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – The term ovarian hyperthecosis (OHT) refers to the presence of nests of luteinized theca cells in the ovarian stroma due to differentiation of the ovarian interstitial cells into steroidogenically active luteinized stromal cells  (<a class="graphic graphic_picture graphicRef75548" href="/z/d/graphic/75548.html" rel="external">picture 1</a>), causing hyperandrogenism. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The majority of patients with OHT are postmenopausal females who present with severe hyperandrogenism, characterized by slowly progressive acne and hirsutism, followed by virilization. Serum total testosterone (T) concentrations are typically &gt;150 ng/dL (&gt;5.2 nmol/L). In fact, a serum total T concentration &lt;5.2 nmol/L (150 ng/dL) rules out hyperthecosis. OHT is rare in premenopausal females. Virilizing signs include male-pattern hair loss, clitoromegaly, lowering of the voice, increased muscle strength, and an anabolic appearance. Unfortunately, most of these signs are irreversible. (See <a class="local">'Severe hyperandrogenism'</a> above and  <a class="medical medical_review" href="/z/d/html/13917.html" rel="external">"Evaluation and management of postmenopausal hyperandrogenism", section on 'Women with virilization or severe hyperandrogenemia'</a>.)</p><p></p><p class="bulletIndent1">Almost all females with OHT present with obesity, insulin resistance, and hyperinsulinemia. These individuals are also at increased risk for type 2 diabetes and, possibly, cardiovascular disease. (See <a class="local">'Obesity and insulin resistance'</a> above and <a class="local">'Biochemical findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Biochemical testing includes serum androgens and gonadotropins followed by ovarian and adrenal imaging if serum total T concentration is &gt;5.2 nmol/L (150 ng/dL). (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The gold standard in confirming the diagnosis of OHT is histopathologic evaluation (luteinized theca cells within the ovarian stroma and absence of neoplasia). The histologic examination is typically performed at the time of laparoscopic bilateral salpingo-oophorectomy. (See <a class="local">'Histology'</a> above and <a class="local">'Diagnosis'</a> above and <a class="local">'Bilateral oophorectomy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – In patients with severe hyperandrogenism, we perform ovarian imaging (transvaginal ultrasound and if needed, magnetic resonance imaging [MRI]) and computed tomography (CT) scan or MRI of the adrenals to rule out testosterone-producing tumors. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Treatment of OHT depends upon age, degree of virilization, and pregnancy goals. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most postmenopausal females and premenopausal females with OHT who have completed childbearing, we suggest laparoscopic bilateral salpingo-oophorectomy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The primary goal of treatment is to eliminate the excessive testosterone production, and surgery is the definitive treatment. GnRH agonist therapy is a reasonable alternative for those who either choose not to have or are not candidates for surgery. (See <a class="local">'Strategies to eliminate/reduce testosterone production'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In premenopausal females with OHT pursuing fertility, ovulation induction can be attempted, but is unlikely to be successful. When not doing ovulation induction, GnRH agonist therapy should be administered to prevent further progression of virilization. Other management issues include treating hirsutism, as well as reducing weight and insulin resistance. (See <a class="local">'Additional therapies'</a> above and <a class="local">'Premenopausal females pursuing fertility'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In spite of dramatic reductions in serum androgen concentrations with surgery or GnRH agonist therapy, little improvement is typically seen in metabolic issues (type 2 diabetes mellitus, obesity, or insulin resistance). (See <a class="local">'Outcomes'</a> above.)</p><p></p><p class="headingAnchor" id="H14646679"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate would like to acknowledge Manubai Nagamani, MD, and Jolande Land, MD, PhD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Nagamani M, Hannigan EV, Dinh TV, Stuart CA. Hyperinsulinemia and stromal luteinization of the ovaries in postmenopausal women with endometrial cancer. J Clin Endocrinol Metab 1988; 67:144.</a></li><li><a class="nounderline abstract_t">Mamoojee Y, Ganguri M, Taylor N, Quinton R. Clinical Case Seminar: Postmenopausal androgen excess-challenges in diagnostic work-up and management of ovarian thecosis. Clin Endocrinol (Oxf) 2018; 88:13.</a></li><li><a class="nounderline abstract_t">Goyal A, Malhotra R, Kulshrestha V, Kachhawa G. Severe hyperandrogenism due to ovarian hyperthecosis in a young woman. BMJ Case Rep 2019; 12.</a></li><li><a class="nounderline abstract_t">Meczekalski B, Szeliga A, Maciejewska-Jeske M, et al. Hyperthecosis: an underestimated nontumorous cause of hyperandrogenism. Gynecol Endocrinol 2021; 37:677.</a></li><li><a class="nounderline abstract_t">Barth JH, Jenkins M, Belchetz PE. Ovarian hyperthecosis, diabetes and hirsuties in post-menopausal women. Clin Endocrinol (Oxf) 1997; 46:123.</a></li><li><a class="nounderline abstract_t">Krug E, Berga SL. Postmenopausal hyperthecosis: functional dysregulation of androgenesis in climacteric ovary. Obstet Gynecol 2002; 99:893.</a></li><li><a class="nounderline abstract_t">Zhang C, Sung CJ, Quddus MR, et al. Association of ovarian hyperthecosis with endometrial polyp, endometrial hyperplasia, and endometrioid adenocarcinoma in postmenopausal women: a clinicopathological study of 238 cases. Hum Pathol 2017; 59:120.</a></li><li><a class="nounderline abstract_t">Meldrum DR, Abraham GE. Peripheral and ovarian venous concentrations of various steroid hormones in virilizing ovarian tumors. Obstet Gynecol 1979; 53:36.</a></li><li><a class="nounderline abstract_t">Friedman CI, Schmidt GE, Kim MH, Powell J. Serum testosterone concentrations in the evaluation of androgen-producing tumors. Am J Obstet Gynecol 1985; 153:44.</a></li><li><a class="nounderline abstract_t">O'Driscoll JB, Mamtora H, Higginson J, et al. A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia. Clin Endocrinol (Oxf) 1994; 41:231.</a></li><li><a class="nounderline abstract_t">Derksen J, Nagesser SK, Meinders AE, et al. Identification of virilizing adrenal tumors in hirsute women. N Engl J Med 1994; 331:968.</a></li><li><a class="nounderline abstract_t">Nagamani M, Lingold JC, Gomez LG, Garza JR. Clinical and hormonal studies in hyperthecosis of the ovaries. Fertil Steril 1981; 36:326.</a></li><li><a class="nounderline abstract_t">Elhassan YS, Idkowiak J, Smith K, et al. Causes, Patterns, and Severity of Androgen Excess in 1205 Consecutively Recruited Women. J Clin Endocrinol Metab 2018; 103:1214.</a></li><li><a class="nounderline abstract_t">Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010; 95:2038.</a></li><li><a class="nounderline abstract_t">Bühler-Christen A, Tischler V, Diener PA, Brändle M. New onset alopecia and hirsutism in a postmenopausal women. Gynecol Endocrinol 2009; 25:324.</a></li><li><a class="nounderline abstract_t">Rousset P, Gompel A, Christin-Maitre S, et al. Ovarian hyperthecosis on grayscale and color Doppler ultrasound. Ultrasound Obstet Gynecol 2008; 32:694.</a></li><li class="breakAll">Nagamani M, Chilvers R. Ultrasonography and diagnosis of polycystic ovary syndrome. In: Ultrasonography in Reproductive Medicine and Infertility, Rizk B (Ed), Cambridge University Press, New York 2010. p.75.</li><li><a class="nounderline abstract_t">Yance VRV, Marcondes JAM, Rocha MP, et al. Discriminating between virilizing ovary tumors and ovary hyperthecosis in postmenopausal women: clinical data, hormonal profiles and image studies. Eur J Endocrinol 2017; 177:93.</a></li><li><a class="nounderline abstract_t">Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod 2018; 33:1602.</a></li><li><a class="nounderline abstract_t">Hall DA, McCarthy KA, Kopans DB. Sonographic visualization of the normal postmenopausal ovary. J Ultrasound Med 1986; 5:9.</a></li><li><a class="nounderline abstract_t">Sherman ME, Lacey JV, Buys SS, et al. Ovarian volume: determinants and associations with cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2006; 15:1550.</a></li><li><a class="nounderline abstract_t">Rosenkrantz AB, Popiolek D, Bennett GL, Hecht EM. Magnetic resonance imaging appearance of ovarian stromal hyperplasia and ovarian hyperthecosis. J Comput Assist Tomogr 2009; 33:912.</a></li><li><a class="nounderline abstract_t">Fujii S, Kiyokawa T, Tsukihara S, et al. Magnetic resonance imaging findings of ovarian stromal hyperthecosis. Acta Radiol 2009; 50:954.</a></li><li><a class="nounderline abstract_t">Kaltsas GA, Mukherjee JJ, Kola B, et al. Is ovarian and adrenal venous catheterization and sampling helpful in the investigation of hyperandrogenic women? Clin Endocrinol (Oxf) 2003; 59:34.</a></li><li><a class="nounderline abstract_t">Dickerson RD, Putman MJ, Black ME, et al. Selective ovarian vein sampling to localize a Leydig cell tumor. Fertil Steril 2005; 84:218.</a></li><li><a class="nounderline abstract_t">Cavlan D, Bharwani N, Grossman A. Androgen- and estrogen-secreting adrenal cancers. Semin Oncol 2010; 37:638.</a></li><li><a class="nounderline abstract_t">Cordera F, Grant C, van Heerden J, et al. Androgen-secreting adrenal tumors. Surgery 2003; 134:874.</a></li><li><a class="nounderline abstract_t">Demidov VN, Lipatenkova J, Vikhareva O, et al. Imaging of gynecological disease (2): clinical and ultrasound characteristics of Sertoli cell tumors, Sertoli-Leydig cell tumors and Leydig cell tumors. Ultrasound Obstet Gynecol 2008; 31:85.</a></li><li><a class="nounderline abstract_t">Pascale MM, Pugeat M, Roberts M, et al. Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumours. Clin Endocrinol (Oxf) 1994; 41:571.</a></li><li><a class="nounderline abstract_t">Chico A, García JL, Matías-Guiu X, et al. A gonadotrophin dependent stromal luteoma: a rare cause of post-menopausal virilization. Clin Endocrinol (Oxf) 1995; 43:645.</a></li><li><a class="nounderline abstract_t">Picón MJ, Lara JI, Sarasa JL, et al. Use of a long-acting gonadotrophin-releasing hormone analogue in a postmenopausal woman with hyperandrogenism due to a hilus cell tumour. Eur J Endocrinol 2000; 142:619.</a></li><li><a class="nounderline abstract_t">Vollaard ES, van Beek AP, Verburg FA, et al. Gonadotropin-releasing hormone agonist treatment in postmenopausal women with hyperandrogenism of ovarian origin. J Clin Endocrinol Metab 2011; 96:1197.</a></li><li><a class="nounderline abstract_t">Brown DL, Henrichsen TL, Clayton AC, et al. Ovarian stromal hyperthecosis: sonographic features and histologic associations. J Ultrasound Med 2009; 28:587.</a></li><li><a class="nounderline abstract_t">Baldini M, Semprini E, Orsatti A, et al. Reduction of insulin resistance after correction of nonneoplastic ovarian virilization. J Endocrinol Invest 1993; 16:285.</a></li><li><a class="nounderline abstract_t">Manieri C, Di Bisceglie C, Fornengo R, et al. Postmenopausal virilization in a woman with gonadotropin dependent ovarian hyperthecosis. J Endocrinol Invest 1998; 21:128.</a></li><li><a class="nounderline abstract_t">Pelusi C, Forlani G, Zanotti L, et al. No metabolic impact of surgical normalization of hyperandrogenism in postmenopausal women with ovarian androgen-secreting tumours. Clin Endocrinol (Oxf) 2013; 78:533.</a></li><li><a class="nounderline abstract_t">Steingold KA, Judd HL, Nieberg RK, et al. Treatment of severe androgen excess due to ovarian hyperthecosis with a long-acting gonadotropin-releasing hormone agonist. Am J Obstet Gynecol 1986; 154:1241.</a></li><li><a class="nounderline abstract_t">Parr JH, Abraham RR, Seed M, et al. The treatment of a hyperandrogenic and virilizing state in an elderly female with a synthetic LHRH agonist. J Endocrinol Invest 1988; 11:433.</a></li><li><a class="nounderline abstract_t">Patel SM, Iqbal N, Kaul S, et al. Effects of metformin and leuprolide acetate on insulin resistance and testosterone levels in nondiabetic postmenopausal women: a randomized, placebo-controlled trial. Fertil Steril 2010; 94:2161.</a></li><li><a class="nounderline abstract_t">Kolterman OG, Insel J, Saekow M, Olefsky JM. Mechanisms of insulin resistance in human obesity: evidence for receptor and postreceptor defects. J Clin Invest 1980; 65:1272.</a></li></ol></div><div id="topicVersionRevision">Topic 7397 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3288650" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hyperinsulinemia and stromal luteinization of the ovaries in postmenopausal women with endometrial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28980338" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical Case Seminar: Postmenopausal androgen excess-challenges in diagnostic work-up and management of ovarian thecosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31852694" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Severe hyperandrogenism due to ovarian hyperthecosis in a young woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33759685" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hyperthecosis: an underestimated nontumorous cause of hyperandrogenism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9135690" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Ovarian hyperthecosis, diabetes and hirsuties in post-menopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11975949" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Postmenopausal hyperthecosis: functional dysregulation of androgenesis in climacteric ovary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27746268" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Association of ovarian hyperthecosis with endometrial polyp, endometrial hyperplasia, and endometrioid adenocarcinoma in postmenopausal women: a clinicopathological study of 238 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/215947" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Peripheral and ovarian venous concentrations of various steroid hormones in virilizing ovarian tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2994479" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Serum testosterone concentrations in the evaluation of androgen-producing tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7923828" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8084355" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Identification of virilizing adrenal tumors in hirsute women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7026294" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical and hormonal studies in hyperthecosis of the ovaries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29342266" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Causes, Patterns, and Severity of Androgen Excess in 1205 Consecutively Recruited Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20375205" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19903039" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : New onset alopecia and hirsutism in a postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18792416" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Ovarian hyperthecosis on grayscale and color Doppler ultrasound.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18792416" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Ovarian hyperthecosis on grayscale and color Doppler ultrasound.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28432270" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Discriminating between virilizing ovary tumors and ovary hyperthecosis in postmenopausal women: clinical data, hormonal profiles and image studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30052961" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3511280" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Sonographic visualization of the normal postmenopausal ovary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16896048" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ovarian volume: determinants and associations with cancer among postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19940659" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Magnetic resonance imaging appearance of ovarian stromal hyperplasia and ovarian hyperthecosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19863423" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Magnetic resonance imaging findings of ovarian stromal hyperthecosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12807501" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Is ovarian and adrenal venous catheterization and sampling helpful in the investigation of hyperandrogenic women?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009186" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Selective ovarian vein sampling to localize a Leydig cell tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21167382" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Androgen- and estrogen-secreting adrenal cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14668717" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Androgen-secreting adrenal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18098335" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Imaging of gynecological disease (2): clinical and ultrasound characteristics of Sertoli cell tumors, Sertoli-Leydig cell tumors and Leydig cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7828344" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8548951" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A gonadotrophin dependent stromal luteoma: a rare cause of post-menopausal virilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10822225" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Use of a long-acting gonadotrophin-releasing hormone analogue in a postmenopausal woman with hyperandrogenism due to a hilus cell tumour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21307133" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Gonadotropin-releasing hormone agonist treatment in postmenopausal women with hyperandrogenism of ovarian origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19389897" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Ovarian stromal hyperthecosis: sonographic features and histologic associations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8514985" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Reduction of insulin resistance after correction of nonneoplastic ovarian virilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9585388" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Postmenopausal virilization in a woman with gonadotropin dependent ovarian hyperthecosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22583337" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : No metabolic impact of surgical normalization of hyperandrogenism in postmenopausal women with ovarian androgen-secreting tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3087210" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Treatment of severe androgen excess due to ovarian hyperthecosis with a long-acting gonadotropin-releasing hormone agonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2974852" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The treatment of a hyperandrogenic and virilizing state in an elderly female with a synthetic LHRH agonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20226444" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effects of metformin and leuprolide acetate on insulin resistance and testosterone levels in nondiabetic postmenopausal women: a randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6997333" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mechanisms of insulin resistance in human obesity: evidence for receptor and postreceptor defects.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
